Brazil Diabetes Drugs Market Analysis

Brazil Diabetes Drugs Market Analysis


$ 3999

The Brazil diabetes drugs market size was valued at $1.54 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $2.67 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Brazil diabetes drug market will grow because the growing aging population, as the population ages, the incidence of diabetes is expected to increase, creating a greater demand for diabetes drugs. The key market players are Ache Laboratorios Farmaceuticos (BRA), Biolab Sanus Farmaceutica (BRA), Cristália Produtos Químicos (BRA), EMS Sigma Pharma (BRA)Boehringer Ingelheim, and others.

ID: IN10BRPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Chandani Patel

Buy Now

Brazil Diabetes Drugs Market Executive Summary

The Brazil diabetes drugs market size was valued at $1.54 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $2.67 Bn in 2030. Brazil is one of the largest economies in the world and has a large population, which has significant implications for its healthcare system and healthcare expenditure. According to the World Health Organization (WHO), Brazil spent approximately 9% of its gross domestic product (GDP) on healthcare in 2017. This is higher than the average for Latin America and the Caribbean, which was approximately 6.6% of GDP in the same year.

Public spending accounts for a significant proportion of healthcare expenditure in Brazil, with the government funding around 46% of all healthcare spending in 2017. Private spending, including out-of-pocket spending by individuals and spending by private health insurance providers, accounted for the remaining 54%.

Brazil has a high prevalence of diabetes, with approximately 21 million people between the ages of 20 and 79 affected, according to the International Diabetes Federation's Diabetes Atlas 2021. The prevalence rate of diabetes in Brazil is 13.4%, which is relatively high compared to other countries. Additionally, there is a significant proportion of undiagnosed cases, with a prevalence rate of 3.8%. The number of deaths attributable to diabetes in Brazil is estimated to be 144,600 in 2021, highlighting the seriousness of the disease in the country. The estimated healthcare expenditure related to diabetes in Brazil for 2021 is USD 26.8 billion. While the Diabetes Atlas does not provide specific data on annual incidence rates for Brazil, the high prevalence of diabetes suggests that there is also a significant incidence rate. This may be influenced by various factors, including age, genetics, lifestyle, and environmental factors. Overall, the high prevalence of diabetes in Brazil is a significant public health issue, with substantial societal and economic implications.

The high prevalence of diabetes in Brazil has a significant impact on the diabetes drugs market in the country. The increasing prevalence of diabetes in Brazil is one of the key drivers of this growth. As the number of people with diabetes continues to rise, there is a corresponding increase in demand for diabetes drugs. Additionally, Brazil's aging population and changing lifestyle habits, such as unhealthy diets and sedentary lifestyles, are contributing to the growing prevalence of diabetes in the country. To meet this growing demand, pharmaceutical companies are investing in research and development of new diabetes drugs and expanding their product portfolios. Insulin and oral hypoglycemic agents are among the most commonly used diabetes drugs in Brazil. The introduction of new drugs, such as SGLT2 inhibitors and GLP-1 agonists, is expected to further drive market growth.

brazil diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

The Brazil diabetes drugs market is driven by several factors, including the high prevalence of diabetes in the country, a growing aging population, and increasing demand for effective treatment options. One of the main drivers of the Brazil diabetes drugs market is the high prevalence of diabetes in the country. According to the International Diabetes Federation, Brazil has one of the largest diabetes populations in the world, with approximately 16.8 million adults living with the disease. This has led to significant demand for diabetes drugs in the country, as patients seek effective treatments to manage their condition.

Furthermore, the growing aging population. As the population ages, the incidence of diabetes is expected to increase, creating a greater demand for diabetes drugs. This is particularly relevant in Brazil, which has one of the fastest-growing aging populations in the world. As a result, there is an increasing need for innovative and effective diabetes drugs to meet the growing demand.

Market Restraints

One of the main challenges is the high cost of diabetes drugs, which can be a significant barrier to access for many patients. While the government provides universal healthcare coverage through the Unified Health System (Sistema Único de Saúde or SUS), the reimbursement rates for diabetes drugs may not always cover the full cost of treatment, leaving some patients without access to essential medications.

Moreover, the increasing use of generic drugs. Brazil has implemented policies to encourage the use of generic drugs, which are often more affordable than brand-name medications. While this has helped to reduce healthcare costs, it can also impact the growth of the diabetes drugs market by limiting the revenue potential for brand-name drugs.

Competitive Landscape

Key Players

  • Ache Laboratorios Farmaceuticos (BRA)
  • Biolab Sanus Farmaceutica (BRA)
  • Cristália Produtos Químicos (BRA)
  • EMS Sigma Pharma (BRA)
  • Boehringer Ingelheim
  • Sanofi
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • AstraZeneca
  • Johnson & Johnson
  • Bayer Pharmaceuticals
  • Novo Nordisk
  • Merck
  • Novartis
  • GlaxoSmithKline

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The regulation of pharmaceutical products in Brazil is overseen by the National Health Surveillance Agency (ANVISA). ANVISA is responsible for evaluating the safety, efficacy, and quality of pharmaceutical products, including diabetes drugs, before they can be approved for sale in the Brazilian market. To be approved for sale in Brazil, diabetes drugs must undergo a rigorous evaluation process, including preclinical and clinical trials. ANVISA reviews data on the drug's safety and efficacy, as well as its manufacturing processes and quality control systems, to ensure that it meets the necessary standards for approval. Once a diabetes drug is approved by ANVISA, it must be registered with the Brazilian Ministry of Health before it can be sold in the country. The Ministry of Health is responsible for setting the reimbursement rates for pharmaceutical products in Brazil, including diabetes drugs.

In Brazil, the government provides universal healthcare coverage through the Unified Health System (Sistema Único de Saúde or SUS). Under the SUS, all Brazilian citizens have access to a range of healthcare services, including medications, at no cost. The Brazilian government negotiates prices for pharmaceutical products, including diabetes drugs, with manufacturers and sets a reimbursement rate for each product. The reimbursement rate is based on the negotiated price and the therapeutic value of the drug. In addition to the SUS, there are also private health insurance plans available in Brazil that may cover the cost of diabetes drugs. The coverage and reimbursement rates for diabetes drugs may vary depending on the specific insurance plan and the drugs prescribed.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

  • Injectable Drugs
    • Insulin Based Injectables
    • Non-insulin Based Injectables
      • Exenatide (Byetta)
      • Dulaglutide (Trulicity)
      • Semaglutide (Ozempic, Wegovy)
      • Liraglutide (`Saxenda, Victoza)
      • Lixisenatide (Adlyxin)
      • Pramlintide (Symlin)
      • Tirzepatide (Mounjaro)
      • Albiglutide (Tanzeum)
  • Oral Drugs
    • Biguanides - Metformin (Glucophage and Glucophase XR)
    • Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
    • Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
    • Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
    • Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
    • Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
    • Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
    • Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
    • Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
    • Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
    • Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

  • Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
  • Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
  • Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 17 March 2023
Updated by: Keta Vora

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up